All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treatment sequencing for anemic myelofibrosis

with Jean-Jacques Kiladjian & Angela Fleischman

Monday, February 26, 2024 | 16:30 CET

This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-02-07T16:33:34.000Z

Gut microbiota differences in MPN

Feb 7, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

Bookmark this article

Changes in gut microbiota composition are associated with a wide range of inflammatory conditions. It is therefore likely that gut changes are involved in the development of myeloproliferative neoplasms (MPN).

Here, we summarize a study by Eickhardt-Dalbøge et al.1 in European Journal of Hematology investigating the overall association of gut microbiota across MPN subtypes and somatic mutations.

Study design1

  • Overall, 227 patients with MPN aged ≥18 years were enrolled between November 2018 and August 2021; 42 healthy controls (HC) were also included
  • Patients had a confirmed diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), preprimary myelofibrosis (MF), MF or post PV/ET-MF, and were grouped according to sub-diagnoses and Janus kinase (JAK)2V617F/calreticulin mutation status.
  • Gut microbiota was analyzed using next-generation sequencing

Key findings1

The median observed bacterial richness of gut microbiota was higher in patients with MPN vs HC (Figure 1).

Figure 1. Median observed significant differences in the richness of gut microbiota* 

CALR, calreticulin; ET, essential thrombocythemia; HC, healthy control; JAK, Janus kinase; MPN, myeloproliferative neoplasia.
*Adapted from Eickhardt-Dalbøge, et al.1

  • The alpha diversity (as measured by the median Inverse Simpson index) did not differ between patients with MPN and HC
    • Patients with MPN and JAK2V617F positive had a significantly lower median Inverse Simpson index vs calreticulin positive patients and HC (21.8 vs 26.3, and 29, respectively, p < 0.05)
  • The bacterial composition in patients with ET resembled that of HC the most, compared with those from patients with PV, preprimary MF, MF, or post PV/ET-MF
  • Patients with MPN had a significantly lower abundance of Firmicutes vs HC (52% vs 59%, p = 0.01) but higher Actinobacteriota (4% vs 2%, p < 0.001)
  • Patients with a high JAK2V617F allele burden had a higher relative abundance of Akkermansia vs patients with a lower allele burden (5% vs 1%, p < 0.01)

Key learnings

  • The gut microbiota in patients with MPN compared with HCs is characterized by a higher observed richness
  • The difference in gut microbiota in patients with MPN vs HC is driven by JAK2V617F; the gut microbiota in calreticulin positive patients with MPN is more similar to HC

  1. Eickhardt-Dalbøge CS, Nielsen H, Fuursted K, et al. JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms. Eur Jrl of Haem. 2024. Online ahead of print. DOI: org/10.1111/ejh.14169

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox